Your browser doesn't support javascript.
loading
Intimate partner violence during pregnancy: To screen or not to screen?
Wong, Janet Yuen-Ha; Zhu, Shiben; Ma, Haixia; Ip, Patrick; Chan, Ko Ling; Leung, Wing Cheong.
Affiliation
  • Wong JY; School of Nursing and Health Studies, Hong Kong Metropolitan University, Kowloon, Hong Kong SAR, China. Electronic address: jyhwong@hkmu.edu.hk.
  • Zhu S; School of Nursing and Health Studies, Hong Kong Metropolitan University, Kowloon, Hong Kong SAR, China.
  • Ma H; School of Nursing and Health Studies, Hong Kong Metropolitan University, Kowloon, Hong Kong SAR, China.
  • Ip P; Department of Paediatrics & Adolescent Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Chan KL; Department of Applied Social Sciences, The Hong Kong Polytechnic University, Hong Kong SAR, China.
  • Leung WC; Department of Obstetrics & Gynaecology, Kwong Wah Hospital, Hospital Authority, Hong Kong SAR, China.
Best Pract Res Clin Obstet Gynaecol ; 97: 102541, 2024 Sep 02.
Article in En | MEDLINE | ID: mdl-39270545
ABSTRACT
Intimate partner violence (IPV) during pregnancy emerges as a compelling and urgent concern within the domain of public health, casting a long shadow over a substantial cohort of women. Its pernicious consequences extend beyond the individual, enveloping the well-being of both the mother and the fetus, giving rise to an elevated risk of preterm birth, low birth weight, fetal harm, and maternal psychological distress, including depression, anxiety, post-traumatic stress disorder, and, tragically, maternal mortality. Despite the prevalence of IPV being comparable to other conditions like gestational diabetes and preeclampsia, a universal screening protocol for IPV remains absent globally. We reviewed the clinical guidelines and practices concerning IPV screening, painstakingly scrutinizing their contextual nuances across diverse nations. Our study unveils multifaceted challenges of implementing universal screening. These hurdles encompass impediments to victim awareness and disclosure, limitations in healthcare providers' knowledge and training, and the formidable structural barriers entrenched within healthcare systems. Concurrently, we delve into the potential biomarkers intricately entwined with IPV. These promising markers encompass inflammatory indicators, epigenetic and genetic influences, and a diverse array of chemical compounds and proteins. Lastly, we discussed various criteria for universal screening including (1) valid and reliable screening tool; (2) target population as pregnant women; (3) scientific evidence of screening programme; and (4) integration of education, testing, clinical services, and programme management to minimise the challenges, which are paramount. With the advancement of digital technology and various biomarkers identification, screening and detecting IPV in clinical settings can be conducted systemically. A systems-level interventions with academia-community-indutrial partnerships can help connect pregnant women to desire support services to avoid adverse maternal and child health outcomes.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Best Pract Res Clin Obstet Gynaecol Journal subject: GINECOLOGIA / OBSTETRICIA Year: 2024 Document type: Article Country of publication: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Best Pract Res Clin Obstet Gynaecol Journal subject: GINECOLOGIA / OBSTETRICIA Year: 2024 Document type: Article Country of publication: Netherlands